AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels Purchases 60,110 Shares

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels acquired 60,110 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was bought at an average cost of $0.18 per share, for a total transaction of $10,819.80. Following the completion of the purchase, the chief executive officer now directly owns 1,552,968 shares in the company, valued at $279,534.24. This represents a 4.03 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

AIM ImmunoTech Stock Performance

Shares of NYSE AIM opened at $0.21 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $0.26 and its two-hundred day moving average is $0.33. The company has a market cap of $13.39 million, a P/E ratio of -0.45 and a beta of -0.36. AIM ImmunoTech Inc. has a 12 month low of $0.16 and a 12 month high of $0.62.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Ascendiant Capital Markets cut their price objective on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Maxim Group cut their price objective on AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday, October 22nd.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in AIM ImmunoTech Inc. (NYSE:AIM) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned 7.92% of AIM ImmunoTech as of its most recent SEC filing. Hedge funds and other institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).